Patient-Friendly Explanation
GLP-1 medications such as semaglutide and tirzepatide help reduce appetite, but their effects fade after the medication is stopped. Studies show that most people regain a significant portion of the lost weight within a year of stopping, because the appetite-suppressing effect ends. This is why a plan for keeping the weight off matters just as much as the medication itself.
Clinical Definition
Discontinuation of GLP-1 receptor agonist therapy is associated with substantial weight regain: in the STEP 1 extension, participants regained approximately two-thirds of their lost weight within one year of stopping semaglutide, with similar findings for tirzepatide in SURMOUNT-4. The regain reflects loss of the pharmacologically induced appetite suppression and energy intake reduction. Mitigation strategies include gradual dose tapering with continued lifestyle support, structured maintenance programmes, and re-initiation if regain exceeds thresholds.
Why It Matters
Starting a GLP-1 is a decision that should include an exit plan. The NuLifeCare Singapore programme pairs medication with lifestyle coaching so that gains are kept after treatment ends.